Media Library

Long-term assessment of the efficacy and safety of inclisiran in patients with high risk of cardiovascular events

Cardiovascular disease (CVD) is the leading cause of death worldwide. Investment in heart health has declined for decades.

A dynamic clinical trial program co-created with healthcare partners worldwide to generate evidence on the impact of cholesterol lowering with Leqvio® (Inclisiran).

Discover the data published in The Lancet on the long-term effect of Cosentyx® (secukinumab) in adults with hidradenitis suppurativa from the SUNRISE and SUNSHINE trials.

Understanding spinal muscular atrophy, a rare, neuromuscular genetic disease.

Modified viruses – including adeno-associated viruses – are an efficient way to transport therapeutic genetic material to affected cells.

Manufacturing of gene therapy is complex. Novartis has developed a reproducible manufacturing process.

Novartis Gene Therapies is the world leader in gene therapy, and is reimagining medicine to transform the lives of patients.

Gene therapy – an innovative approach to treating rare, genetic diseases.

Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness.

Kymriah® (pronounced: Kim-RYE-ah) is the first FDA-approved CAR-T cell therapy available in the US

The JULIET clinical trial is a global, multi-center Phase II registration trial investigating CTL019 (tisagenlecleucel) for use in diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma (NHL). The Novartis-sponsored JULIET trial was conducted in collaboration with the University of Pennsylvania to evaluate the safety and efficacy of CTL019 in adult patients with relapsed or refractory (r/r) DLBCL. Relapsed/refractory DLBCL is an aggressive (fast-growing), complex and difficult-to-treat disease, and patients with DLBCL often have worse prognosis than other forms of NHL.